Dapagliflozin reduced CV death or HHF irrespective of baseline NT-proBNP and hsTnT levels, yielding greater absolute risk reductions in patients above the median (1.9% vs 0% for NT-proBNP).
RCT (n=14,565)
double-blind
randomized
Does dapagliflozin reduce the composite of cardiovascular death or hospitalization for heart failure in patients with type 2 diabetes mellitus across different baseline NT-proBNP and hsTnT levels?
In patients with type 2 diabetes, higher baseline NT-proBNP and hsTnT identify those at greater risk for CV death or heart failure hospitalization who derive larger absolute benefit from dapagliflozin.
AIMS: Dapagliflozin reduced the risk of the composite of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus in DECLARE-TIMI 58. We hypothesized that baseline N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hsTnT) levels would help identify patients who are at higher baseline risk and we describe the treatment effects of dapagliflozin in patients according to their baseline NT-proBNP and hsTnT levels. METHODS AND RESULTS: This was a pre-specified biomarker study from DECLARE-TIMI 58, a randomized, double-blind, placebo-controlled CV outcomes trial of dapagliflozin. Baseline NT-proBNP and hsTnT levels were measured in the TIMI Clinical Trials Laboratory in 14 565 patients. Among the included patients, 9143 patients (62.8%) were male, 1464 (10.1%) had a history of heart failure and the mean age was 63.9 years. The median baseline NT-proBNP and hsTnT levels were 75 pg/mL interquartile range (IQR) 35-165 and 10.2 pg/mL (IQR 6.9-15.5), respectively. Patients with higher NT-proBNP and hsTnT quartiles had higher rates of CV death/HHF (Q4 vs. Q1: NT-proBNP: 4-year Kaplan-Meier event rates 13.7% vs. 1.0%; hsTnT: 11.8% vs. 1.4%; P-trend <0.001). Dapagliflozin consistently reduced the relative risk of CV death/HHF regardless of baseline NT-proBNP (P-interaction 0.72) or hsTnT quartiles (P-interaction 0.93). Given their higher baseline risk, patients with NT-proBNP and/or hsTnT levels above the median derived larger absolute risk reductions with dapagliflozin (NT-proBNP 1.9% vs. 0%, P-interaction 0.010; hsTnT 1.8% vs. 0.1%, P-interaction 0.026). CONCLUSION: Patients with type 2 diabetes mellitus and higher NT-proBNP or hsTnT levels are at increased risk of CV death and HHF. Dapagliflozin reduced the relative risk of CV death/HHF irrespective of NT-proBNP and hsTnT levels, with greater absolute risk reductions seen in patients with higher baseline biomarker levels.
Zelniker et al. (Wed,) conducted a rct in type 2 diabetes mellitus (n=14,565). Dapagliflozin vs. placebo was evaluated on composite of cardiovascular (CV) death or hospitalization for heart failure (HHF). Dapagliflozin reduced CV death or HHF irrespective of baseline NT-proBNP and hsTnT levels, yielding greater absolute risk reductions in patients above the median (1.9% vs 0% for NT-proBNP).